EcoDrugPlus

Matrix Metallopeptidase 8

Ensembl ID : ENSCJAG00000003743
Gene Symbol: MMP8
5 Cross references
111 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Matrix Metallopeptidase 9

Ensembl ID : ENSCJAG00000017207
Gene Symbol: MMP9
5 Cross references
216 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mechanistic Target Of Rapamycin Kinase

Ensembl ID : ENSCJAG00000002191
Gene Symbol: MTOR
5 Cross references
224 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Melanocortin 1 Receptor

Ensembl ID : ENSCJAG00000046104
Gene Symbol: MC1R
3 Cross references
159 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Melanocortin 3 Receptor

Ensembl ID : ENSCJAG00000011249
Gene Symbol: MC3R
5 Cross references
139 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Melanocortin 4 Receptor

Ensembl ID : ENSCJAG00000022877
Gene Symbol: MC4R
5 Cross references
229 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Melatonin Receptor 1a

Ensembl ID : ENSCJAG00000020300
Gene Symbol: MTNR1A
5 Cross references
216 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Membrane Metalloendopeptidase

Ensembl ID : ENSCJAG00000000959
Gene Symbol: MME
5 Cross references
236 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Methionyl Aminopeptidase 2

Ensembl ID : ENSCJAG00000002740
Gene Symbol: METAP2
5 Cross references
228 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Microtubule Associated Protein Tau

Ensembl ID : ENSCJAG00000019935
Gene Symbol: MAPT
5 Cross references
226 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSCJAG00000015743
Gene Symbol: MAPK1
3 Cross references
214 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Mitogen-Activated Protein Kinase 10

Ensembl ID : ENSCJAG00000005621
Gene Symbol: MAPK10
5 Cross references
222 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).